Efficacy and safety of ossein-hydroxyapatite complex versus calcium carbonate to prevent bone loss

References

• Consensus Development Conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646–50
   PubMed Web of Science ®Google Scholar
• Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761–7
   PubMed Web of Science ®Google Scholar
• Balk EM, Adam GP, Langberg VN, et al. Global dietary calcium intake among adults: a systematic review. Osteoporos Int 2017;28:3315–24
   PubMed Web of Science ®Google Scholar
• Seifert-Klauss V, Fillenberg S, Schneider H, Luppa P, Mueller D, Kiechle M. Bone loss in premenopausal, perimenopausal and postmenopausal women: results of a prospective observational study over 9 years. Climacteric 2012;15:433–40
   PubMed Web of Science ®Google Scholar
• Chapurlat RD, Garnero P, Sornay-Rendu E, Arlot ME, Claustrat B, Delmas PD. Longitudinal study of bone loss in pre- and perimenopausal women: evidence for bone loss in perimenopausal women. Osteoporos Int 2000;11:493–8
   PubMed Web of Science ®Google Scholar
• Lo JC, Burnett-Bowie SA, Finkelstein JS. Bone and the perimenopause. Obstet Gynecol Clin North Am 2011;38:503–17
   PubMed Web of Science ®Google Scholar
• Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 2014;25:2359–81
   PubMed Web of Science ®Google Scholar
• Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 2017;12:43
   PubMed Web of Science ®Google Scholar
• Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab 2019;104:1595–622
   PubMed Web of Science ®Google Scholar
• Shea B, Wells G, Cranney A, et al. Calcium supplementation on bone loss in postmenopausal women. Cochrane Database Syst Rev 2004;1:CD004526
   Google Scholar
• Schmidt KH, Worner UM, Buck HJ. Examination of new bone growth on aluminium oxide implant contact surfaces after oral administration of ossein-hydroxyapatite compound to rats. Curr Med Res Opin 1988;11:107–15
   PubMed Web of Science ®Google Scholar
• Annefeld M, Caviezel R, Schacht E, Schicketanz KH. The influence of ossein-hydroxyapatite compound (‘Ossopan’) on the healing of a bone defect. Curr Med Res Opin 1986;10:241–50
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Ciria-Recasens M, Cancelo-Hidalgo MJ, et al. Efficacy of ossein-hydroxyapatite complex compared with calcium carbonate to prevent bone loss: a meta-analysis. Menopause 2009;16:984–91
   PubMed Web of Science ®Google Scholar
• Ciria-Recasens M, Blanch-Rubió J, Coll-Batet M, et al. Comparison of the effects of ossein-hydroxyapatite complex and calcium carbonate on bone metabolism in women with senile osteoporosis: a randomized, open-label, parallel-group, controlled, prospective study. Clin Drug Investig 2011;31:817–24
   PubMed Web of Science ®Google Scholar
• Pelayo I, Haya J, De la Cruz JJ, et al. Raloxifene plus ossein-hydroxyapatite compound versus raloxifene plus calcium carbonate to control bone loss in postmenopausal women: a randomized trial. Menopause 2008;15:1132–8
   PubMed Web of Science ®Google Scholar
• Durance RA, Parsons V, Atkins CJ, Hamilton EBD, Davies C. A trial of calcium supplements (Ossopan) and ashed bone. Clin Trial J 1973;10:67–74
   Google Scholar
• Castelo-Branco C, Pons F, Vicente JJ, Sanjuán A, Vanrell JA. Preventing postmenopausal bone loss with ossein-hydroxyapatite compounds. Results of a two-year, prospective trial. J Reprod Med 1999;44:601–5
   PubMed Web of Science ®Google Scholar
• Rüegsegger P, Keller A, Dambacher MA. Comparison of the treatment effects of ossein-hydroxyapatite compound and calcium carbonate in osteoporotic females. Osteoporosis Int 1995;5:30–4
   PubMed Web of Science ®Google Scholar
• Chevalley T, Rizzoli R, Nydegger V, Slosman D, Rapin CH, Michel JP. Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients. Osteoporosis Int 1994;4:245–52
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Dávila Guardia J. Use of ossein-hydroxyapatite complex in the prevention of bone loss: a review. Climacteric 2015;18:29–37
   PubMed Web of Science ®Google Scholar
• Stèpán JJ, Mohan S, Jennings JC, Wergedal JE, Taylor AK, Baylink DJ. Quantitation of growth factors in ossein-mineral-compound. Life Sci 1991;49:79–84
   Web of Science ®Google Scholar
• Saadeh PB, Mehrara BJ, Steinbrech DS, et al. Transforming growth factor-ß1 modulates the expression of vascular endothelial growth factor by osteoblasts. Am J Physiol 1999;277:628–37
   Google Scholar
• Bonjour JP, Ammann P, Chevalley T, Rizzoli R. Protein intake and bone growth. Can J Appl Physiol 2001;26:153–66
   Google Scholar
• Fernández-Pareja A, Hernández-Blanco E, Pérez-Maceda JM, Riera Rubio VJ, Palazuelos JH, Dalmau JM. Prevention of osteoporosis: four-year follow-up of a cohort of postmenopausal women treated with an ossein-hydroxyapatite compound. Clin Drug Investig 2007;27:227–32
   PubMed Web of Science ®Google Scholar
• Conti F, Piscitelli P, Italiano G, et al. Adherence to calcium and vitamin D supplementations: results from the ADVICE Survey. Clin Cases Miner Bone Metab 2012;9:157–60
   PubMedGoogle Scholar
• Carnevale V, Nieddu L, Romagnoli E, et al. Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian survey. Osteoporos Int 2006;17:478–83
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Cortés X, Ferrer M. UNICAD study investigators. Treatment persistence and compliance with a combination of calcium and vitamin D. Climacteric 2010;13:578–84
   PubMed Web of Science ®Google Scholar
• Pfister AK, Welch CA, WuLu JT, Jr, Hager KA, Saville PD. An assessment of postmenopausal women’s adherence to calcium with vitamin D supplements. J Appl Res 2008;8:143–50
   Google Scholar
• Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637–45
   PubMed Web of Science ®Google Scholar